The following is a reconciliation between basic and diluted weighted average shares outstanding:


	13 Weeks Ended				26 Weeks Ended
(In thousands)	August 2, 2025		August 3, 2024		August 2, 2025		August 3, 2024
Numerator:
Net income and numerator for basic EPS	$	77,633	$	77,264	$	12,734	$	145,014
Numerator for diluted EPS	$	77,633	$	77,264	$	12,734	$	145,014

Denominator:
Denominator for basic EPS - weighted average shares		170,756		193,661		175,156		195,048
Add: Dilutive effect of stock options and non-vested restricted stock		903		4,096		1,326		4,358
Denominator for diluted EPS - adjusted weighted average shares		171,659		197,757		176,482		199,406
Anti-dilutive shares (1)		4,151		393		3,518		350

(1) For all periods presented, anti-dilutive shares relate to stock options and unvested restricted stock.

Dilutive and anti-dilutive shares related to share-based compensation. Refer to Note 9, Share-Based Payments, to the Consolidated Financial Statements for additional information regarding share-based compensation.

On March 14, 2025, the Company entered into an accelerated share repurchase agreement (the "ASR Agreement") with Bank of America, N.A. ("Bank of America"). Pursuant to the terms of the ASR Agreement, on March 17, 2025, the Company made an aggregate payment of $200 million to Bank of America and received an aggregate initial delivery of approximately 14.5 million shares of its common stock. At final settlement on June 16, 2025, the Company received an additional 3.9 million shares. The cumulative repurchases under the ASR agreement totaled 18.4 million shares, in the aggregate, at an average price of $10.86. The aforementioned repurchased shares have been recorded as treasury stock.